Incruse Ellipta

Umeclidinium bromide, the active ingredient in Incruse Ellipta, is a long‑acting muscarinic antagonist presented as an inhalation powder for inhalation use. It provides sustained bronchodilation and helps improve lung function for maintenance treatment of chronic obstructive pulmonary disease in adult patients.

GNH USA supplies Incruse Ellipta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and offers reliable global distribution, with regulatory approvals across the European Union.

Incruse Ellipta, a long‑acting muscarinic antagonist, is indicated for chronic obstructive pulmonary disease (COPD) management.

Chronic obstructive pulmonary disease (COPD): Improves lung function, reduces symptoms and decreases the frequency of exacerbations in patients with stable COPD. Stable COPD: Provides once‑daily bronchodilation to maintain airway patency. COPD maintenance therapy: Reduces the need for rescue medication and improves overall health status.

Common Side Effects: - Cough - Dry mouth - Nasopharyngitis - Headache - Constipation - Throat irritation

Serious or Rare Side Effects: - Paradoxical bronchospasm - Severe allergic reaction (rash, swelling, anaphylaxis) - Chest pain or palpitations - Persistent wheezing - Acute respiratory distress - Unexplained fever

Before initiating therapy, consider the following precautions: - Assess lung function: Perform baseline spirometry to determine disease severity. - Monitor symptoms: Watch for worsening dyspnea or increased sputum production. - Cardiovascular caution: Use carefully in patients with known arrhythmias or ischemic heart disease. - Hypersensitivity: Avoid in individuals with a documented allergy to umeclidinium or any component of the inhaler. - Not a rescue inhaler: Do not substitute for short‑acting bronchodilators during acute attacks. - Store at ambient temperature: Keep the device in its original packaging, protect from moisture and direct heat.

Umeclidinium may interact with other medications; consider the following:

Major Interactions (Avoid): - Concurrent use of other anticholinergic inhalers: May increase anticholinergic load and risk of side effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): Potentially raise systemic exposure.

Moderate Interactions (Monitor Closely): - Beta‑2 agonists: Additive bronchodilator effect; monitor for excessive tremor or tachycardia. - Theophylline: May require serum level checks due to possible pharmacodynamic interaction. - Systemic anticholinergic agents (e.g., atropine, scopolamine): Observe for heightened anticholinergic effects.